Infliximab as first-line therapy in severe pediatric Crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 43, Issue 3, 2006, Pages 388-390

  De Ridder, Lissy ^a   Benninga, Marc A ^a   Taminiau, Jan A J M ^a   Hommes, Daniël W ^b  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; ENEMA; INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

ARTICLE; CASE REPORT; CLINICAL FEATURE; COLITIS; COLONOSCOPY; CROHN DISEASE; DISEASE SEVERITY; FEMALE; HAIR LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; PEDIATRICS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SIGMOIDOSCOPY; TREATMENT OUTCOME;

ABDOMINAL PAIN; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BLOOD SEDIMENTATION; CHILD; COLON; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DUODENOSCOPY; DUODENUM; ESOPHAGUS; FEMALE; GASTROSCOPY; HUMANS; ILEUM; INTESTINAL MUCOSA; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SIGMOIDOSCOPY; STOMACH; WEIGHT LOSS;

EID: 33748567119     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000226369.31956.bf     Document Type: Article

References (11)

1. Derkx B, Taminiau J, Radema S, et al. Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance IFX for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1542-9.
3. Van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
4. Stephens MC, Shepansky MA, Mamula P, et al. Safety and steroid-sparing experience using IFX for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-11.
5. de Ridder L, Escher JC, Bouquet J, et al. IFX therapy in 30 patients with refractory pediatric Crohn's disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr 2004;39:46-52.
6. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to IFX in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
7. Hommes D, Baert F, van Assche G, et al. Management of recent onset Crohn's disease: a controlled, randomized trial comparing step-up and top-down therapy (abstract). Gastroenterology 2005;129(1):371.
8. Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
9. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocortcoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
10. Bascietto C, De Angelis L, Bizzarri B. Infliximab as a first-line therapy in newly diagnosed Crohn's Disease (CD) promotes long-term sustained remission and alters the course of the disease. J Pediatr Gastroenterol Nutr 2005;40:PG2-16.
11. Mary J, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut 1989;30:983-9.